Royal Cosun has completed its investment in PeakBridge's Growth Fund II, strengthening its position in the agri-foodtech sector. The investment supports Cosun's strategy to accelerate growth in plant-based ingredients and sustainable food solutions. PeakBridge is an impact fund focusing on scalable, patented technologies addressing environmental and nutritional challenges in the agri-food sector. The partnership will leverage Cosun's expertise and network to support PeakBridge-funded companies whilst enhancing Cosun's presence in agri-foodtech. The investment targets innovative companies in ingredient innovations, alternative protein technologies, digitisation and novel farming systems. Maaike van den Maagdenberg, Director of Cosun Corporate Development, stated the move aligns with Cosun's growth and transformation objectives in green and health-promoting ingredients.

Enzymit and Cosun achieve pilot-scale biomanufacturing of hyaluronic acid. Enzymit, a synbio company pioneering cell-free biomanufacturing, has partnered with Cosun, a leader in sustainable plant-based ingredients, to successfully produce hyaluronic acid (HA) at a 200-liter pilot scale. Using an enzyme-only, cell-free process, they generated multi-kilogram quantities of high-purity HA, demonstrating greater efficiency and consistency than traditional fermentation methods. Hyaluronic acid is a highly valuable biopolymer used in dermal fillers, wound healing, drug delivery, and tissue engineering. With the global market projected to reach nearly $16 billion by 2035, the demand for high-quality biomaterials is rapidly growing. Enzymit's innovative process is the first to enable manufacturers to control HA's size during production. Using standardized enzymatic steps, they can produce HA ranging from about 10 kDa to 4 MDa with narrow size distribution, simply by adjusting process parameters - no need to change enzymes or organisms. Marie Dobenesque, CTO of Cosun RD&I, said, "We're proud to support Enzymit's journey from lab to pilot scale. Their process development and factory operation were successful using existing assets, showing this cell-free technology is becoming an industrial reality in record time." This platform leverages AI-designed enzymes to synthesize complex bioproducts faster, cleaner, and more efficiently - without living cells. Gideon Lapidoth, CEO of Enzymit, emphasizes that this breakthrough not only advances HA production but also signals a future where molecular biomanufacturing is driven by precision, removing biological bottlenecks.

Revyve's proteins can replace eggs and certain additives in processed foods, helping firms clean up labels and ensure security of supply.